MAY 12·Stock Titan▲
Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys
Cellectar Biosciences, Inc. (NASDAQ: CLRB) Chief Operating Officer Jarrod Longcor recently increased his holdings by purchasing 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant. These open-market transactions, which occurred on May 7, 2026, increased his direct ownership to 20,451 common shares and 36,149 warrants. The warrants are exercisable for common stock at $2.88, with varying expiration terms of one, two, and five years from stockholder approval.
APR 15·National Today▲
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer
Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial of CLR 125, an Auger-emitting radioconjugate, for refractory triple-negative breast cancer (TNBC). This trial will evaluate the safety, tolerability, and preliminary efficacy of CLR 125 at three different dose levels and regimens. The company aims to address the significant unmet medical need for targeted therapies in this aggressive form of breast cancer.
